Prices delayed by at least 15 minutes | Print


Camurus AB (CAMX)

Sell: 481.8 SEK|Buy: 482.6 SEK|Change: 14.20 (-2.86%)

Open 

499.6 SEK


Previous close 

497 SEK


Trade high 

501.5 SEK


Volume 

97,785


Year high 

599.50 SEK


Year low 

246.00 SEK


Dividend yield 

-


Market capitalisation 

27.82 bn SEK


P/E ratio 

66.27


ISIN 

SE0007692850


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 06/05/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Camurus AB- 2.86
More...

Company profile

Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.